Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-05-20 Major Shareholding Noti…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 94 pages 2.2MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of Truist Securities, Inc. and Truist Financial Corporation in Telix Pharmaceuticals Limited, including voting power, relevant interests, registered holders, and consideration. The document also includes an annexure with a lock-up agreement related to a public offering of American Depositary Shares. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice, which fits the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory filing about share ownership levels crossing thresholds.
2024-05-20 English
Becoming a substantial holder from MS 357 pages 3.3MB
Regulatory Filings
2024-05-20 English
Becoming a substantial holder 95 pages 2.9MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001, detailing the substantial shareholding interests of Jefferies LLC and related entities in Telix Pharmaceuticals Limited. It includes voting power details, relevant interests, registered holders, consideration paid, and associates. The document is a regulatory filing notifying the market and regulators of a change in substantial shareholding, which fits the definition of a Major Shareholding Notification. It is not an annual report, earnings release, or any other financial report type. The document is substantive and not merely an announcement or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-05-20 English
Becoming a substantial holder 5 pages 285.6KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and is described as a 'Notice of initial substantial holder' under the Corporations Act 2001 Section 671B. It details the substantial shareholding of First Sentier Investors Holdings Pty Limited and its associates in Telix Pharmaceuticals Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. The document is a regulatory filing notifying the market and regulators of a substantial shareholding crossing a threshold. It does not contain financial statements, management discussion, or other report content. It is not an announcement of a report publication but a formal regulatory disclosure. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is substantial and contains detailed information about shareholding changes, consistent with MRQ filings.
2024-05-20 English
Telix has Filed Registration Statement for Proposed US IPO 2 pages 138.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement by Telix Pharmaceuticals Limited about filing a registration statement (Form F-1) with the U.S. SEC for a proposed initial public offering (IPO) of American Depository Shares. It describes the offering process, the underwriters, and legal disclaimers. There are no financial statements, detailed financial data, or management discussion of results. The document is an announcement of a capital raising event and filing, not the actual registration statement or prospectus itself. Therefore, it fits best under Capital/Financing Update (CAP). The document length (7198 characters) supports it being a full announcement rather than a brief notice. Confidence is high due to clear references to IPO filing and offering details.
2024-05-19 English
Application for quotation of securities - TLX 6 pages 19.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references previous announcements such as Appendix 3B and 3G. The content focuses on the administrative process of listing newly issued shares and securities on the exchange, rather than reporting financial results or corporate governance matters. This type of document is a regulatory announcement related to capital markets and securities listing, specifically an application for quotation of securities. According to the filing definitions, this fits best under 'Share Issue/Capital Change' (SHA) as it relates to new share issues and capital changes. The document length is sufficient and contains detailed information about the securities issued and their quotation application, confirming it is not merely an announcement of a report but a formal filing about capital changes.
2024-05-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.